Hydroxychloroquine (Indication Antiphospholipid Syndrom)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13674
R53129		 Ye, 2017 Premature delivery during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Co-administration Indication HCQ: Antiphospholipid syndrome (APS) 0.86 [0.43;1.73] C 18/112   20/110 38 112
ref
S13718
R53440		 Sciascia, 2016 Preterm live births <37 weeks throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Antiphospholipid syndrome (APS) 0.17 [0.04;0.80] C 2/34   16/60 18 34
ref
Total 2 studies 0.45 [0.09;2.11] 56 146
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ye, 2017Ye, 2017 0.86[0.43; 1.73]3811259%ROB confusion: seriousROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Sciascia, 2016Sciascia, 2016 0.17[0.04; 0.80]183441%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 71% 0.45[0.09; 2.11]561460.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 2 Tags Adjustment   - No  - No 0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 2 Co-administrationCo-administration 0.86[0.43; 1.73]38112 -NAYe, 2017 1 Indication HCQ   - Antiphospholipid syndrome (APS)  - Antiphospholipid syndrome (APS) 0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 2 All studiesAll studies 0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.45[0.09; 2.11]5614671%NAYe, 2017 Sciascia, 2016 20.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Clowse (Antiphospholipid syndrome)Clowse (Antiphospholipid syndrome) 0.88[0.09; 8.97]NA-whatever (meta-analysis)during pregnancy (anytime or not specified)studies-9 Tian (Antiphospholipid antibody syndrome)Tian (Antiphospholipid antibody syndrome) Out of scale0.43[0.13; 1.37]50%-whatever (meta-analysis)during pregnancy (anytime or not specified)studies2 metaPregmetaPreg Out of scale0.45[0.09; 2.11]71%146--Ye, 2017 Sciascia, 2016 20.510.01.0